CoChat

GLP-1R agonist therapy for diabetes: benefits and potential risks

Samson, Susan L., Garber, Alan · 2013 · Current Opinion in Endocrinology, Diabetes & Obesity

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Abstract

PURPOSE OF REVIEW: Glucagon-like peptide 1 receptor (GLP-1R) agonists provide good glycemic control combined with low hypoglycemia risk and weight loss. Here, we summarize the recently published data for this therapy class, focusing on sustainability of action, use in combination with basal insulin, and the efficacy of longer acting agents currently in development. The safety profile of GLP-1R agonists is also examined. RECENT FINDINGS: GLP-1R agonists provide sustained efficacy and their combination with basal insulin is well tolerated, providing additional glycemic control and weight benefits compared with basal insulin alone. Data suggest that the convenience of longer acting agents may be at the expense of efficacy. Despite the initial concerns, most evidence indicates that GLP-1R agonists do not increase the risk of pancreatitis or thyroid cancer. However, the extremely low incidence of these events means further investigations are required before a causal link can be eliminated. Large-scale clinical trials investigating the long-term cardiovascular safety of this therapy class are ongoing and may also provide important insights into pancreatic and thyroid safety. SUMMARY: GLP-1R agonists offer sustained glycemic efficacy, weight loss benefits, and a low risk of hypoglycemia. The results of ongoing trials should help to clarify the safety of this therapy class.

Overview

Integrity signals

Registry

Crossref · 10.1097/med.0b013e32835edb32

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 56

Metadata

Authors
Samson, S. L., & Garber, A.
Affiliations
Baylor College of Medicine (US)
Corresponding author
Samson, Susan L.
Venue
Current Opinion in Endocrinology, Diabetes & Obesity
Published
2013-04
Volume
20
Issue
2
Pages
87-97
ISSN
1752-296X (ISSN-L)
OpenAlex
W2123127609
Cited by
55
References
42
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 9 · 2014: 9 · 2013: 3
FWCI
1.27
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Intarcia Therapeutics
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079638)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, hypoglycemia risk, pancreatitis risk, thyroid cancer risk, cardiovascular safety, drug safety
MeSH terms
Glucagon-Like Peptide-2 Receptor, Liraglutide, Exenatide, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucagon-Like Peptides, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Insulin, Male, Pancreatitis, Peptides, Recombinant Fusion Proteins, Thyroid Neoplasms, Venoms, Randomized Controlled Trials as Topic, Treatment Outcome, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1R agonist therapy for diabetes: benefits and potential risks. https://app.cochat.ai/papers/10.1097/med.0b013e32835edb32
The paper
Samson, S. L., & Garber, A. (2013). GLP-1R agonist therapy for diabetes: benefits and potential risks. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0b013e32835edb32

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.